

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/199551 A1

(51) International Patent Classification:

A61K 38/07 (2006.01) A61K 31/616 (2006.01)
A61P 9/10 (2006.01) A61K 38/06 (2006.01)
A61K 9/00 (2006.01) A61K 47/26 (2006.01)
A61K 31/4365 (2006.01) A61K 47/54 (2017.01)
A61K 31/4439 (2006.01) A61K 47/55 (2017.01)
A61K 31/4545 (2006.01)

(21) International Application Number:

PCT/CN2022/082100

(22) International Filing Date:

21 March 2022 (21.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/164,336 22 March 2021 (22.03.2021) US

(71) Applicant: **LUMOSA THERAPEUTICS CO., LTD.**
[CN/CN]; 4F, No. 3-2, Park Street, Nangang District,
Taipei, Taiwan 11503 (CN).

(72) Inventors: **LIN, Jung-Chin**; 4F, No. 3-2, Park Street, Nan-
gang District, Taipei, Taiwan 11503 (CN). **YEH, Sheng-
Wen**; 4F, No. 3-2, Park Street, Nangang District, Taipei,
Taiwan 11503 (CN). **PENG, Shiqi**; 4F, No. 3-2, Park Street,


Nangang District, Taipei, Taiwan 11503 (CN). **ZHAO,
Ming**; 4F, No. 3-2, Park Street, Nangang District, Taipei,
Taiwan 11503 (CN). **CHOU, David Chih-Kuang**; 4F, No.
3-2, Park Street, Nangang District, Taipei, Taiwan 11503
(CN).

(74) Agent: **INTELIGHT IP LAW FIRM**; Suite 1710, Tower
B, Techart Plaza, No. 30 Xueyuan Road, Haidian District,
Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: DC009 FOR TREATING ACUTE ISCHEMIC STROKE



DC009	Placebo	P value
-4.3 $\pm$ 3	3.5 $\pm$ 2.1	P=0.007

FIG. 6

(57) Abstract: The present invention is directed to a method of treat-
ing acute ischemic stroke in a human comprising administering one of
more low doses of DC009, wherein the dose is about 0.01-0.075 mg/
kg/dose. The low dose administration is safe and effective in treating
acute ischemic stroke in a human subject.

WO 2022/199551 A1

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*